G

Generate Biomedicines

Generate Biomedicines is a biotech startup focused on AI-driven drug discovery, specifically in the generation and optimization of therapeutic proteins. The company aims to significantly reduce the time required for drug discovery, with a pipeline that includes a Phase 3 clinical trial for severe asthma and multiple oncology candidates with FDA Fast Track designation.

Total raised
$700M
tracked to date
Latest round
Series C
Jun 27, 2026
Known investors
2
led by Nvidia

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q2 2026 USA Funding Report

Read the Q2 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q2-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q2 2026 USA Funding Report</a>

Funding history

  1. 1
    $700MSeries CJun 27, 2026

    Led by Nvidia

    Announcement ↗

Investors in Generate Biomedicines

Backers from this company's tracked funding rounds.

  • NNvidiaLead investorVC firm
  • AAmgenVC firm

Generate Biomedicines in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile